Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ELF4 antisense oligonucleotide
- Development stage
- Preclinical
- Lead developer
- University of Pennsylvania
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
ELF4 antisense oligonucleotide is an antisense oligonucleotide (ASO) designed to target and knock down the expression of E74-like ETS transcription factor 4 (ELF4), an ETS-domain transcription factor. Developed by researchers at the University of Pennsylvania, this therapeutic candidate is being investigated for the treatment of chronic kidney disease (CKD) and kidney fibrosis. ELF4 is upregulated in kidney fibrosis models and human CKD samples, primarily expressed by natural killer (NK) cells where it directly regulates interferon-gamma (IFNG) expression and indirectly alters macrophage polarization. In preclinical mouse models of folic acid- and cisplatin-induced kidney injury, administration of the ELF4 antisense oligonucleotide has been shown to reduce collagen accumulation, suppress pro-fibrotic gene expression, and protect against kidney fibrosis and dysfunction.
- Other names
- Elf4 ASOElf-4 ASOElf 4 ASOElf4 antisense oligonucleotideElf-4 antisense oligonucleotideElf 4 antisense oligonucleotide
02
Targets
ETS (ETS transcription factor family)
Beyond the preview
Go deeper on ELF4 antisense oligonucleotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ELF4 antisense oligonucleotide.